Apr 22, 2021 12:14pm Prevencio’s HART tests rely on machine learning to analyze blood samples for evidence of obstructive coronary artery disease, Kawasaki disease, the risk of heart attack or stroke, and more. (Pixabay)(Pixabay / PublicDomainPictures)
With high hopes resting on Prevencio’s AI-driven blood tests, it’s only logical that the company would turn to Atlas Genomics to help shoulder the load.
Prevencio tapped Atlas CLIA-certified molecular diagnostic laboratory in Seattle to support the commercial rollout of its HART blood test technology, which can now be ordered for research use. The financial terms of the partnership were not disclosed.
Prevencio develops blood tests that identify cardiovascular diseases and other heart-related risks by using machine learning to parse dozens of protein levels and other biomarkers at once.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft’s AI-computing Cloud
April 21, 2021 GMT
KIRKLAND, Wash. (BUSINESS WIRE) Apr 21, 2021
Prevencio, Inc. today announces an Agreement with Atlas Genomics to commercially launch its highly accurate, AI-driven HART blood tests for heart disease and risk of heart attack, stroke, and cardiovascular death. The HART blood tests are now available and can be ordered through your physician.
Atlas Genomics is a CLIA-certified, high complexity diagnostic lab providing the highest quality of testing, service, and technology. Prevencio’s and Atlas’ partnership incorporates the use of Microsoft’s Azure AI-computing cloud for HART algorithm processing, scoring, report generation and secure physician delivery of Prevencio’s HART test reports. Additional terms of the deal are not disclosed.